220 related articles for article (PubMed ID: 31780812)
21. Clinical presentation and prognostic analysis of Chinese patients with systemic light chain amyloidosis with liver involvement.
Zhang LL; Shen KN; Zhang CL; Qiu Y; Miao HL; Feng J; Cao XX; Zhang L; Zhou DB; Li J
Leuk Res; 2019 Nov; 86():106226. PubMed ID: 31541941
[TBL] [Abstract][Full Text] [Related]
22. Autologous stem cell transplantation and IgM amyloidosis.
Valente M; Roy V; Lacy MQ; Dispenzieri A; Gertz MA
Leuk Lymphoma; 2006 Jun; 47(6):1006-12. PubMed ID: 16840189
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
[TBL] [Abstract][Full Text] [Related]
24. Composite monoclonal B-cell lymphocytosis and MYD88 L265P-positive lymphoplasmacytic lymphoma in a patient with IgM light chain amyloidosis: Case report.
Oishi N; Inoue T; Odate T; Mochizuki K; Ohashi K; Kirito K; Kondo T
Pathol Int; 2020 Jul; 70(7):458-462. PubMed ID: 32323419
[TBL] [Abstract][Full Text] [Related]
25. IGVL gene region usage correlates with distinct clinical presentation in IgM vs non-IgM light chain amyloidosis.
Sidana S; Dasari S; Kourelis TV; Dispenzieri A; Murray DL; King RL; McPhail ED; Ramirez-Alvarado M; Kumar SK; Gertz MA
Blood Adv; 2021 Apr; 5(8):2101-2105. PubMed ID: 33877297
[TBL] [Abstract][Full Text] [Related]
26. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
27. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092
[No Abstract] [Full Text] [Related]
28. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.
Sidana S; Tandon N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M; Murray DL; Kourelis TV; Buadi FK; Kapoor P; Gonsalves W; Warsame R; Lacy MQ; Kyle RA; Rajkumar SV; Kumar SK; Leung N
Br J Haematol; 2019 May; 185(4):701-707. PubMed ID: 30836444
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
[TBL] [Abstract][Full Text] [Related]
30. First report of MYD88
Chakraborty R; Novak AJ; Ansell SM; Muchtar E; Kapoor P; Hayman SR; Dispenzieri A; Buadi FK; Lacy MQ; King RL; Gertz MA
Amyloid; 2017 Mar; 24(sup1):42-43. PubMed ID: 28434299
[No Abstract] [Full Text] [Related]
31. Ten-year survivors in AL amyloidosis: characteristics and treatment pattern.
Muchtar E; Gertz MA; Lacy MQ; Go RS; Buadi FK; Dingli D; Grogan M; AbouEzzeddine OF; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Gonsalves W; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Zeldenrust S; Kyle RA; Rajkumar SV; Kumar SK; Dispenzieri A
Br J Haematol; 2019 Dec; 187(5):588-594. PubMed ID: 31298751
[TBL] [Abstract][Full Text] [Related]
32. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Sidana S; Tandon N; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
Leukemia; 2018 Mar; 32(3):729-735. PubMed ID: 28919633
[TBL] [Abstract][Full Text] [Related]
33. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
Tovar N; Rodríguez-Lobato LG; Cibeira MT; Magnano L; Isola I; Rosiñol L; Bladé J; Fernández de Larrea C
Amyloid; 2018 Jun; 25(2):79-85. PubMed ID: 29482381
[TBL] [Abstract][Full Text] [Related]
34. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
35. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
[TBL] [Abstract][Full Text] [Related]
36. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy - A Single-Center Cohort Study of 227 Patients.
Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
[TBL] [Abstract][Full Text] [Related]
37. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time.
Sidiqi MH; Aljama MA; Buadi FK; Warsame RM; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Hogan WJ; Gertz MA
J Clin Oncol; 2018 May; 36(13):1323-1329. PubMed ID: 29558277
[TBL] [Abstract][Full Text] [Related]
38. Transplantation for IgM amyloidosis and IgM myeloma.
Gertz MA; Hayman SR; Buadi FK
Clin Lymphoma Myeloma; 2009 Mar; 9(1):77-9. PubMed ID: 19362980
[TBL] [Abstract][Full Text] [Related]
39. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis.
Lilleness B; Ruberg FL; Mussinelli R; Doros G; Sanchorawala V
Blood; 2019 Jan; 133(3):215-223. PubMed ID: 30333122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
